These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 15476153

  • 1. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.
    Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, Baxter K, Zinsmeister AR.
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):895-904. PubMed ID: 15476153
    [Abstract] [Full Text] [Related]

  • 2. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
    Tack J, Middleton SJ, Horne MC, Piessevaux H, Bloor JS, Meyers NL, Palmer RM.
    Aliment Pharmacol Ther; 2006 Jun 01; 23(11):1655-65. PubMed ID: 16696817
    [Abstract] [Full Text] [Related]

  • 3. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.
    George AM, Meyers NL, Hickling RI.
    Aliment Pharmacol Ther; 2008 May 01; 27(9):830-7. PubMed ID: 18284648
    [Abstract] [Full Text] [Related]

  • 4. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study.
    Lembo AJ, Cremonini F, Meyers N, Hickling R.
    Aliment Pharmacol Ther; 2010 May 01; 31(9):979-90. PubMed ID: 20163375
    [Abstract] [Full Text] [Related]

  • 5. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR.
    Gastroenterology; 2007 Sep 01; 133(3):761-8. PubMed ID: 17854590
    [Abstract] [Full Text] [Related]

  • 6. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome.
    Scarpellini E, Tack J.
    Expert Opin Investig Drugs; 2008 Nov 01; 17(11):1663-70. PubMed ID: 18922103
    [Abstract] [Full Text] [Related]

  • 7. Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial.
    Spiller RC, Meyers NL, Hickling RI.
    Dig Dis Sci; 2008 Dec 01; 53(12):3191-200. PubMed ID: 18465239
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
    Shin A, Acosta A, Camilleri M, Boldingh A, Burton D, Ryks M, Rhoten D, Zinsmeister AR.
    Clin Gastroenterol Hepatol; 2015 Apr 01; 13(4):701-8.e1. PubMed ID: 25148765
    [Abstract] [Full Text] [Related]

  • 11. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE, Camilleri M, Szarka LA, McKinzie S, Burton D, Thomforde G, Baxter K, Zinsmeister AR.
    Neurogastroenterol Motil; 2007 Oct 01; 19(10):821-30. PubMed ID: 17539894
    [Abstract] [Full Text] [Related]

  • 12. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P.
    J Gastroenterol Hepatol; 2007 Aug 01; 22(8):1183-9. PubMed ID: 17688659
    [Abstract] [Full Text] [Related]

  • 13. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
    Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G.
    Gastroenterology; 2000 Mar 01; 118(3):463-8. PubMed ID: 10702196
    [Abstract] [Full Text] [Related]

  • 14. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?
    Sweetser S, Camilleri M, Linker Nord SJ, Burton DD, Castenada L, Croop R, Tong G, Dockens R, Zinsmeister AR.
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun 01; 296(6):G1299-306. PubMed ID: 19342506
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.
    Meyers NL, Hickling RI.
    Drugs R D; 2008 Jun 01; 9(1):37-63. PubMed ID: 18095752
    [Abstract] [Full Text] [Related]

  • 17. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.
    Acosta A, Camilleri M, Kolar G, Iturrino J, Szarka LA, Boldingh A, Burton D, Ryks M, Rhoten D, Zinsmeister AR, Spence SC, Gottesdiener K, Bouras EP, Vazquez-Roque MI.
    Clin Gastroenterol Hepatol; 2015 Dec 01; 13(13):2312-9.e1. PubMed ID: 26001337
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Motility abnormalities in irritable bowel syndrome.
    DuPont AW, Jiang ZD, Harold SA, Snyder N, Galler GW, Garcia-Torres F, DuPont HL.
    Digestion; 2014 Dec 01; 89(2):119-23. PubMed ID: 24503633
    [Abstract] [Full Text] [Related]

  • 20. Renzapride in IBS: is efficacy in the eye of the beholder?
    Ford AC.
    Aliment Pharmacol Ther; 2010 Jul 01; 32(1):113-4; author reply 114-5. PubMed ID: 20597877
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.